

Journal of Health Monitoring · 2017 2(3)  
DOI 10.17886/RKI-GBE-2017-062  
Robert Koch Institute, Berlin

**Authors:**

Christin Heidemann, Christa Scheidt-Nave



## Prevalence, incidence and mortality of diabetes mellitus in adults in Germany – A review in the framework of the Diabetes Surveillance

### Abstract

Continuous monitoring of the key epidemiological indicators of diabetes is necessary for evaluating the magnitude of diabetes as a public health problem, but is currently not being undertaken in Germany. A comprehensive literature review covering the last decades was conducted to give an overview of population-based studies reporting on diabetes prevalence, diabetes incidence, and diabetes-related mortality among adults in Germany. This review differentiates between known and unknown diabetes, but not between individual types of diabetes.

Numerous studies have identified a considerable increase in the prevalence of known diabetes among the adult population over time. Until the 1960s, the prevalence of known diabetes remained below 1%. However, current nationwide estimates for Germany are much higher and range between 7.2% (population aged 18 to 79 years) based on health examination surveys of the Robert Koch Institute (RKI), 8.9% (population aged 18 years and over) based on RKI telephone health interview surveys and 9.9% (among all age groups) based on statutory health insurance data. Few available estimates point to an increase in the incidence of known diabetes since the 1960s. For example, a comparison of data from the diabetes register of the former German Democratic Republic (GDR) in 1960 with current follow-up data from RKI survey participants shows that incidence rates increased from 1.2 (all age groups) to 6.9 (population aged 18 to 79 years) per 1,000 person-years. Data on diabetes-related mortality are also scarce, but indicate that excess mortality persists among people with known diabetes compared to those in the same age group without the condition, despite the finding of decreasing mortality rates among people with known diabetes. For example, the mortality rate based on early data from the GDR diabetes register was 1.9-fold higher among people with known diabetes than among the general population; current mortality follow-up data of RKI survey participants show a 1.7-fold higher mortality rate among people with known diabetes compared to those without the condition. Given the limited data that are currently available and the considerable variation of diagnostic criteria, it is not possible to estimate time trends in the prevalence, incidence or mortality of unknown diabetes.

An extension of available health monitoring approaches and an improved use of existing data sources for secondary analysis are needed for a reliable evaluation of dynamics in diabetes epidemiology in Germany. To achieve these goals, a national diabetes surveillance system is currently being established under the auspices of the RKI.

DIABETES MELLITUS · PREVALENCE · INCIDENCE · MORTALITY · EPIDEMIOLOGY

**Info box 1: Prevalence [66, 67]**

The frequency of a specific disease among a population at a particular time. It is usually expressed as a percentage (proportion) of a given population.

**Since the 1960s, the proportion of people with known diabetes (prevalence) has increased almost ten-fold.**

**1. Introduction**

Diabetes mellitus is a metabolic disorder involving a disruption of the regulation of blood glucose levels [1]. It results in chronically elevated blood glucose concentrations, which, if left untreated or treated insufficiently, can lead to serious complications including myocardial infarction, stroke, renal failure, blindness and amputations. Clearly, it can therefore reduce people's quality of life and life expectancy, while also producing high levels of costs for health care systems [2].

Information about the spread of diabetes mellitus (Prevalence, [Info box 1](#)) is particularly relevant to attempts to classify the disorder within the public health context. Around 3,500 years ago, descriptions of symptomatology demonstrate that severe cases of diabetes were rare [3]. Even as late as the first half of the 20th century, the prevalence of diabetes in Europe was still estimated to be considerably lower than 1% [4, 5]. However, since the 1960s, there has been a marked increase in the prevalence of diabetes in Germany that has led it to be viewed as endemic [6]. In fact, an alarming increase in the prevalence of diabetes has occurred throughout the world [7]; so much so that this situation has been described as a 'diabetes pandemic' [8, 9]. In addition to known (medically diagnosed) diabetes, unknown (medically undiagnosed) diabetes also plays an important role because it is suggested that a large number of cases go unreported [10]. There are estimations that point to a period of latency between the onset of diabetes and a medical diagnosis of the condition of at least six years on average [11].

During this time, a considerable proportion of people with unknown diabetes begin to develop diabetes-specific complications [12-14]. However, changes to the criteria used for diagnosis ([Info box 4](#)) and diabetes screening could lead to a shift in the ratio of unknown to known cases over time.

Time trends in diabetes prevalence are directly associated with developments in the rate of new cases (Incidence rate, [Info box 2](#)) and the death rate (Mortality rates, [Info box 3](#)) within a given population [15]. In turn, the incidence rate is closely associated with changes in behaviour (such as dietary habits, physical activity and associated body weight) as well as living conditions (such as economic, social and environmental factors at the individual and regional level) that have an impact on diabetes development. Apart from increases in life expectancy in the general population, the mortality rate among people with diabetes is particularly influenced by the quality of diabetes care. In addition, demographic changes (such as population ageing and migration) play a role in epidemiological developments linked to diabetes. In Germany – as in most other countries – information about the interplay of the prevalence, incidence and mortality rates linked to diabetes is limited due to the lack of continuous data collection [16-18].

This article aims to summarise available data on the prevalence, incidence and mortality of diabetes among adults in Germany and to describe time trends wherever possible. It considers both known and unknown diabetes. This article also explores approaches that could be used to continuously monitor key indicators of dynamics in diabetes epidemiology in Germany.

**Info box 2: Incidence [66, 67]**

The frequency of new cases among a population within a given time period. It is often expressed as a percentage (proportion) of new cases within a population (cumulative incidence) or the number of new cases per 1,000 person-years (incidence rate).

*Cumulative incidence (%)*: The number of new cases related to the number of people at risk; in other words, the percentage of a population that does not have the disease in question at the beginning of a defined period (for example a ten-year study period) but that could develop the disease during this time. As an example, people who already have diabetes at the start of a study period are excluded from calculations of cumulative incidence.

*Incidence rate (per 1,000 person-years)*: The number of new cases related to the person-time at risk; in other words, the number of new cases related to the time span accumulated by all of the people who are at risk of developing the disease and among whom it could possibly be observed during the study period. As an example, not everyone is at risk of getting diabetes during the entire study period because they may either be diagnosed with diabetes or die from other causes before the study has been completed.

**2. Method**

A narrative literature review of the PubMed bibliographic database was conducted to identify studies that have published data on diabetes prevalence, incidence and mortality in Germany. In addition, we hand-searched the bibliographies of relevant original research articles and literature reviews. However, only studies that directly provided or permitted calculation of the following data on prevalence, incidence or mortality were included within this review: prevalence as a percentage of the population with diabetes ([Info box 1](#)); incidence as a rate, in other words, as the number of new cases of diabetes per 1,000 person-years ([Info box 2](#)); age-standardised or age-adjusted mortality rate comparing all-cause mortality rates among people with diabetes to rates among people without diabetes or in the general population ([Info box 3](#)). Given the limited availability of data on incidence, studies were also included if they provided current nationwide estimates of the cumulative incidence ([Info box 2](#)). However, studies that only provided data on children or adolescents, or on population subgroups at particular risk of diabetes (such as people with obesity, a history of heart disease or those living in nursing homes), were not included in the review. Depending on the study in question, 'diabetes' was usually defined as all types of the disorder or just type 2 diabetes – the most predominant form of diabetes in adults [10, 18]. Detailed descriptions of the study populations and the definition of diabetes used in the studies included in this review are set out in the figures and tables presented below.

**3. Prevalence****3.1 Prevalence of known diabetes**

Numerous estimates of the prevalence of known diabetes are available from various studies that have been conducted over recent decades. The individual estimates of prevalence from studies undertaken after around 1960 are summarised in [Figure 1](#) (for national-level studies) and in [Figure 2](#) (for regional studies). Overall, the available data demonstrate that the prevalence of known diabetes has strongly increased over time.

Until the beginning of the 20th century, prevalence estimates of known diabetes were based on mortality and clinical case statistics; these identified a prevalence of between 0.2% and 0.4% [4, 5, 19]. Estimates made during the Second World War, which were derived from statistics covering the provision of insulin and dietary supplements to diabetes patients, suggest a decrease in prevalence. In part, this is due to the increased mortality among people with diabetes due to deficient or low-quality medication and food supplies as well as a higher susceptibility to infection [5, 19].

Living conditions improved in the 1950s and 1960s. This went along with an increased intake of high-calorie foods, reduced levels of physical activity and increases in the prevalence of overweight and obesity in the population; at the same time, life expectancy among people with diabetes increased due to improved treatment. As a result, the prevalence of known diabetes increased considerably [5, 6, 20-22]. In addition, diabetes screening activities mainly conducted in East Germany (the former German Democratic Republic, GDR) and to a

**Info box 3: Mortality** [66, 67]

The frequency of deaths among a population within a given time period. This is often provided as a percentage (proportion) of deaths within a population (cumulative mortality) or the number of deaths per 1,000 person-years (mortality rate).

*Age-standardised or age-adjusted mortality rates:*

Age-standardisation or age-adjustment is used to compare the rate of death among population groups with different age structures. These statistical methods can provide an assessment of a mortality rate that is independent of demographic differences. As an example, in this article age-standardised or age-adjusted mortality rates are compared between people with diabetes and the general population or people without diabetes. The resulting higher risk of death (known as the standardised mortality ratio or hazard ratio, [Table 3](#)) is referred to here as the excess mortality of people with diabetes compared to the reference group.

lesser degree in West Germany had a role in increasing the prevalence of known diabetes due to better detection of undiagnosed diabetes [4, 6, 20, 22, 23]. Data from the GDR diabetes register, which covers almost all diabetes cases treated in the country between 1960 and 1989, show a continuous increase in prevalence during this period from 0.6% to 4.1% [23]. While there is no comparable database to describe time trends for West Germany during this time period, estimates that are available from various sources suggest that the prevalence in West Germany increased by a similar magnitude [24-27].


From 1990 until about 2000, data available from population studies offer no evidence of a further rise in the prevalence of known diabetes. Population-based surveys conducted in the Augsburg region (Cooperative Health Research in the Region of Augsburg, KORA; Monitoring Trends and Determinants in Cardiovascular Disease, MONICA) between 1989/1990 and 1999-2001 [28] and a comparison of data from the German nationwide survey (Nationwide Health Survey, NUS) conducted between 1990 and 1992 with data from the German National Health Interview and Examination Survey 1998 (GNHIES98) conducted between 1997 to 1999 [29] do not demonstrate an increased prevalence. Moreover, even after comparisons over time were expanded to include data from the RKI telephone health interview surveys (GSTel) conducted between 2002 and 2005, no increase over time was observed [30].

During the first decade of the 21st century, data from periodically repeated nationwide examination, telephone and postal surveys [31-33], as well as trend analyses based on insurance data from AOK Baden-Württemberg and

AOK Hesse [34, 35], all demonstrate a clear increase in prevalence. According to data from the RKI examination surveys conducted between 1997 and 1999 (GNHIES98) and 2008 and 2011 (German Health Interview and Examination Survey for Adults, DEGS1), the prevalence of known diabetes rose from 5.2% to 7.2% among persons aged 18 to 79 years [31]. Health insurance data covering everyone insured by AOK Hesse between 2000 and 2009 showed a rise from 6.5% to 9.7% [35]. Differences in prevalence estimates derived from these and other studies conducted over a similar time period ([Figures 1 and 2](#)) are most likely attributable to differences in criteria used to define diabetes and in the groups of people included in the studies in question, which can differ according to the data source ([Info box 5](#)). Consistent across studies based on survey and health insurance data, about one third of the observed increase is attributable to demographic ageing [31, 35]. Further reasons for the current increase in prevalence may be improvements in early disease detection (such as increased awareness among doctors or changes in diagnostic criteria: see [Info box 4](#)), partial improvements made to diabetes care (such as the introduction of Disease Management Programmes) [36, 37] and the associated longer life expectancy. In addition, changes in the prevalence of behavioural risk factors also need to be considered. However, these demonstrate partly opposing trends and – according to a summary measure provided by the German Diabetes Risk Score – provide no evidence of a current increase in the overall level of risk [38].

Establishing a continuous monitoring system for the prevalence of known diabetes among adults in Germany

**Figure 1**  
Nationwide studies providing data  
on the prevalence of known diabetes  
among adults in Germany




Study population	Definition of known diabetes
● RKI interview surveys (via telephone): ≥18-year-olds, N~8,000 to~22,000 [32, 79-82]	Self-report of physician-diagnosed diabetes
■ RKI interview survey (online/paper-based): ≥18-year-olds, N=23,345 [83]	Self-report of having diabetes (not including gestational diabetes) in the last 12 months
▲ RKI examination surveys: 18-79-year-olds, N~7,000 [31]	Self-report of physician-diagnosed diabetes or of anti-diabetic medication
◆ Postal surveys: 18-79-year-olds, N~1,500 [33]	Self-report of diabetes diagnosis (≥1 visit to a doctor per quarter or regular anti-diabetic medication)
● Claims data from physicians on insurees from all statutory health insurance funds: all ages, N~70 million [40]	Physician-diagnosed diabetes (ICD-10 E10-E14 in ≥2 of 4 quarters with additional ICD-tag 'G' (confirmed) in outpatient diagnoses)
○ Sample of insurees from all statutory health insurance funds: all ages, N~65 million [39]	Physician-diagnosed diabetes (ICD-10 E10-E14 with additional ICD-tag 'G' (confirmed) in outpatient diagnoses)
▲ Sample of insurees from the AOK: all ages, N~24 million [84]	Physician-diagnosed type 2 diabetes (ICD-10 E11-E14 in ≥2 of 4 quarters in outpatient diagnoses) or prescription of anti-diabetic medication (in ≥2 of 4 quarters)
■ Sample of insurees from 6 statutory health insurance funds: all ages, N~15 million [85]	Physician-diagnosed diabetes or prescription of anti-diabetic medication
◆ Sample of insurees from the Techniker Krankenkasse: all ages, N~5.4 million [86]	Physician-diagnosed type 2 diabetes (ICD-10 E11 with additional ICD-tag 'G' (confirmed) in ≥2 quarters in outpatient diagnoses or in ≥1 quarter in inpatient diagnoses for the period between Jan 2006 and Dec 2008)
□ HYDRA patient sample from general practices: ≥16-year-olds, N=43,549 [87]	Physician data on diabetes diagnosis on the day the study was conducted
△ DETECT patient sample from general practices: ≥18-year-olds, N=55,518 [88]	Physician data on diabetes diagnosis on the day the study was conducted or anti-diabetic medication
◇ GEMCAS patient sample from general practices: ≥18-year-olds, N=35,869 [89]	Physician-diagnosed diabetes
○ Health Survey East/West 91: 25-69-year-olds, N=7,448 [29] (own calculation)	Self-report of diabetes diagnosis
□ GCP surveys (West Germany): 25-69-year-olds, N~5,000 [26] (own calculation)	Self-report of diabetes diagnosis
● GDR diabetes register (East Germany): all ages, N~17 million [22, 23, 51]	Physician-diagnosed diabetes

For graphical presentation, the midpoint of the respective study period (0.5 yearly steps) is entered into the horizontal axis.

AOK Allgemeine Ortskrankenkasse (a large statutory health insurance company)  
 GCP German Cardiovascular Prevention Study  
 GDR German Democratic Republic  
 DETECT Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment  
 DHP Deutsche Herz-Kreislauf-Präventionsstudie  
 GEMCAS German Metabolic and Cardiovascular Risk Project  
 HYDRA Hypertension and Diabetes Risk Screening and Awareness  
 ICD-10 International statistical classification of diseases and related health problems, 10<sup>th</sup> revision  
 RKI Robert Koch Institute  
 TK Techniker Krankenkasse (a statutory health insurance company)



**Figure 2**  
Regional studies providing data on the prevalence of known diabetes among adults in Germany



Study population	Definition of known diabetes
● Sample of insurees from the AOK, Berlin: all ages, N=730,196 [90]	Physician-diagnosed type 2 diabetes (verified)
■ Sample of insurees from the AOK, Baden-Wuerttemberg: all ages, N~4 million [34]	Physician-diagnosed type 2 diabetes (ICD-10 E11, E12 or E14 in ≥3 of 4 quarters) or prescription of anti-diabetic medication (ATC A10A or A10B ≥2 per year or 1 per year with a diagnosis of type 2 diabetes or plus glucose or HbA1c measurements in the same quarter)
▲ Sample of insurees from the AOK, Hesse: all ages, N=300,000 [35, 91-93]	Physician-diagnosed diabetes (in ≥3 of 4 quarters) or prescription of anti-diabetic medication (≥2 per year or 1 per year with a diagnosis of diabetes or plus glucose or HbA1c measurements in the same quarter)
◆ Sample of insurees from the AOK, Dortmund: all ages, N=6,478 [27]	Physician-diagnosed diabetes (in ≥2 of 4 quarters) or prescription of anti-diabetic medication (≥4 per year) or blood glucose measurement (in ≥3 of 4 quarters)
○ ESTHER patient sample from general practices, Saarland: 50-75-year-olds, N=9,953 [94]	Physician-diagnosed diabetes or anti-diabetic medication
□ SESAM 2 patient sample from general practices, Saxony: 2-102-year-olds, N = 8,877 [95]	Physician-diagnosed diabetes
┆ GHS, Mainz-Bingen: 35-74-year-olds, N=15,010 [96]	Physician-diagnosed diabetes or diabetes therapy
● CARLA, Halle: 45-74-year-olds, N=1,382 [97] ■ SHIP, Western Pomerania: 45-74-year-olds, N=2,247 [97]	Self-report of diabetes diagnosis or of anti-diabetic medication and age at diagnosis >30 years
▲ DHS, Dortmund: 45-74-year-olds, N=883 [97] ◆ HNR, Essen/Bochum/Mulh.: 45-74-year-olds, N=4,734 [97]	Self-report of physician-diagnosed diabetes or of anti-diabetic medication (verified)
○ KORA S4, Augsburg: 45-74-year-olds, N=2,442 [97]	Self-report of physician-diagnosed diabetes or of anti-diabetic medication (verified)
□ KORA F4, Augsburg: 35-39-year-olds, N=1,653 [47] △ KORA S4, Augsburg: 55-74-year-olds, N=1,353 [98]	Self-report of physician-diagnosed diabetes or of anti-diabetic medication (verified)
◇ Population sample from 5 federal states: 18-70-year-olds, N=2,150 [99]	Self-report of diabetes diagnosis or of diabetes therapy
● GDR diabetes register, district of Neubrandenburg: all ages, N~620,000 [100]	
■ GDR diabetes register, East Berlin: all ages, N~1.3 million [101]	
▲ GDR diabetes register, district of Erfurt: all ages, N~1.2 million [102]	Physician-diagnosed diabetes
◆ GDR diabetes register, district of Schwerin: all ages, N~590,000 [103]	
— GDR diabetes register, district of Rostock: all ages, N~830,000 [6]	
× Diabetes Screening, Munich: all ages, N=789,000 [25]	Self-report of diabetes diagnosis
+ Serial examination, Herrenberg: all ages, N=10,036 [24]	Physician-diagnosed diabetes

For graphical presentation, the midpoint of the respective study period (0.5 yearly steps) is entered into the horizontal axis. Additional studies exclusively reported on sex-specific prevalences [16, 28, 104, 105].

- AOK Allgemeine Ortskrankenkasse (a large statutory health insurance company)
- ATC Anatomical Therapeutic Chemical Classification
- CARLA Cardiovascular Disease, Living and Ageing in Halle
- HbA1c glycated haemoglobin
- GDR German Democratic Republic
- GHS Gutenberg-Gesundheitsstudie
- DHS Dortmund Health Study
- ESTHER Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung
- HNR Heinz Nixdorf Recall Study
- ICD-10 International statistical classification of diseases and related health problems, 10<sup>th</sup> revision
- KORA Cooperative Health Research in the Region of Augsburg
- SESAM Sächsische Epidemiologische Studien in der Allgemeinmedizin
- SHIP Study of Health in Pomerania

#### Info box 4: Laboratory criteria for the diagnosis of diabetes over time

<sup>1</sup> Fasting glucose: Glucose measured after a period of fasting that lasts for at least 8 hours or at least 10 hours/overnight depending on the guideline in question. Measurements are made using venous plasma.

<sup>2</sup> OGTT glucose: Glucose measured in the oral glucose tolerance test (OGTT), i.e. 2 hours (or 1 hour according to earlier guidelines [69]) after drinking a solution of 75g glucose (or 50g/100g glucose according to earlier guidelines [68]) after a period of fasting. Measurements are made using venous plasma.

<sup>3</sup> HbA<sub>1c</sub>: Glycated haemoglobin, i.e. form (A<sub>1</sub>) of haemoglobin to which the glucose links to (glycation). The proportion of HbA<sub>1c</sub> compared to the total level of haemoglobin represents the average glucose concentration over the past few weeks. Measurements are made using whole blood.

Some guidelines also refer to measurements of random glucose for the diagnosis of diabetes (i.e. glucose measured at any time of the day, regardless of the time since the last food intake) using  $\geq 11.1$  mmol/l ( $\geq 200$ mg/dl) as a cut-off in the presence of classic symptoms of diabetes (unexplained weight loss, excessive urine excretion, excessive thirst).

For further information on laboratory methods, requirements for measurement and repeated testing, please refer to the detailed descriptions provided in the references. The same applies to diagnostic criteria based on glucose measurements in capillary or whole blood as well as for the criteria used to diagnose gestational diabetes.

	Fasting glucose <sup>1</sup>	1h-OGTT glucose <sup>2</sup>	2h-OGTT glucose <sup>2</sup>	HbA <sub>1c</sub> <sup>3</sup>
WHO 1965 [68]	–	–	$\geq 7,2$ mmol/l ( $\geq 130$ mg/dl)	–
NDDG 1979 [69]	$\geq 7,8$ mmol/l ( $\geq 140$ mg/dl)	$\geq 11,1$ mmol/l ( $\geq 200$ mg/dl)	$\geq 11,1$ mmol/l ( $\geq 200$ mg/dl)	
WHO 1980 [70]	$\geq 8,0$ mmol ( $\geq 145$ mg/dl)	–	$\geq 11,0$ mmol/l ( $\geq 198$ mg/dl)	
WHO 1985 [71]	$\geq 7,8$ mmol/l ( $\geq 140$ mg/dl)			
ADA 1997 [72]	$\geq 7,0$ mmol/l ( $\geq 126$ mg/dl)		$\geq 11,1$ mmol/l ( $\geq 200$ mg/dl)	
WHO 1999 [73]				
ADA 2010 [74]				
DDG 2010 [75]		$\geq 48$ mmol/mol ( $\geq 6,5\%$ )		
WHO 2011 [76]				

Abbreviations: ADA: American Diabetes Association, DDG: German Diabetes Association, NDDG: National Diabetes Data Group, WHO: World Health Organization

appears feasible. Time trend analyses need to consider continuously collected data from nationwide, population-based RKI interview and examination surveys [31, 32] as well as routine data for secondary analysis available at the national level within the statutory health insurance system (Info box 5) [39, 40]. A comprehensive analysis is essential in this context, since the available data sources all have specific strengths and limitations (Info box 5).

### 3.2 Prevalence of unknown diabetes

Some studies have been conducted over recent decades on unknown diabetes; Table 1 summarises the prevalence estimates that they have identified. A number of major systematic diabetes screenings and serial examinations that were conducted during the 1960s are included as examples. Numerous other screening activities

have been summarised elsewhere [4, 19, 20, 41]. In general, the data on unknown diabetes is fragmented and a reliable analysis of trends is not feasible due to the varying criteria used to define the condition.

The earliest estimates of the prevalence of unknown diabetes are based on screenings undertaken during the 1950s and 1960s, which were mainly based on urine glucose screening (glucosuria screening) in combination with heterogeneous forms of follow-up examinations. These earlier estimates usually suggest a prevalence of below 1% or a ratio of persons with known diabetes to newly diagnosed cases of about 1:1 [42]. As of the 1970s, glucosuria screening, which has a low sensitivity, moderate specificity and an unfavourable cost-benefit ratio, became increasingly less important [23, 43, 44].

Subsequent estimates of prevalence start to become available during the mid-1990s. These are mainly derived from regional cohort studies and are partly based on

### Info box 5: Primary and secondary data

**Definition:** In contrast to primary data, secondary data are data that are not directly collected for a research interest that was specified in advance or that are evaluated differently from their intended usage [64].

**Data sources:** Primary data sources that are important for the identification of the frequency of diseases include 1) the examination and interview surveys conducted regularly at nationwide level by the Robert Koch Institute (RKI) [77] and 2) ongoing cohort studies such as the GNC that is being undertaken in 18 study centres [50]. Secondary data sources include administrative data routinely collected within the German social security and health system for documentation and reimbursement. Of particular importance in this context are nationwide routine data that come from multiple statutory health insurers such as 1) the data reported to the German Federal Insurance Office (BVA) for the Morbidity-oriented Risk Structure Compensation (Morbi-RSA). Since 2014, these data have been merged for research purposes in accordance with the Data Transparency Regulation (DaTraV) and are held by the German Institute of Medical Documentation and Information (DIMDI). Another important source of nationwide routine data is 2) the data collected on people with statutory health insurance sent for billing purposes by contract doctors and that are regularly analysed by the Central Research Institute of Ambulatory Health Care in Germany (Zi) [65].

**Advantages and limitations:** Primary data sources such as the RKI examination surveys often include information on health-related behaviours and laboratory measures. This permits monitoring of risk factor profiles and undiagnosed conditions, such as unknown diabetes. However, these surveys miss certain groups of people (e.g. nursing home residents, people who are very old) and not everyone who is

*Continued on next page*

fasting blood glucose levels in combination with glucose values measured 2 hours after an oral glucose tolerance test (2h-OGTT glucose) or at a random time (random glucose) (Info box 4). However, some are based on measurements of glycated haemoglobin (HbA<sub>1c</sub>). This method is now recognised as a criterion for diagnosis (Info box 4) and it is especially employed in epidemiological studies because HbA<sub>1c</sub> measures are not affected by fasting time. Nevertheless, as the studies employed different methods, and each method relates to a different aspect of glucose metabolism [45], they also identified different groups of people. Therefore, study results differ considerably depending on the method employed by the study in question [46]. Different study regions or age ranges within individual study populations makes a direct comparison of prevalence even more difficult. For example, the KORA F4 study that covers the Augsburg region employed fasting glucose levels and 2h-OGTT glucose measurements and identified a prevalence of unknown diabetes of 2.0% among 35- to 59-year-olds and of 3.9% among 35- to 79-year-olds between 2006 and 2008 [47, 48]. Using the same criteria the Study of Health in Pomerania (SHIP)-TREND, which covers Western Pomerania and was conducted between 2008 and 2012, found a prevalence of 7.1% among 35- to 79-year-olds [48]. Data from nationwide RKI health examination surveys that are based on HbA<sub>1c</sub> measurements identified a 3.4% prevalence of unknown diabetes between 1997 and 1999 and a 2.0% prevalence between 2008 and 2011 among 18- to 79-year-olds [49]. This study, which is still the only one to have employed a comparable definition of unknown diabetes at two points in time, identi-

fied a decrease in the prevalence of unknown diabetes over the last decade.

In order to continuously monitor the prevalence of unknown diabetes in the adult population in Germany, it is essential that studies employ a definition that is comparable over time. Currently, this can only be done by continuing the RKI health examination surveys, which are conducted at relatively wide intervals. Nevertheless, cohort studies, such as the German National Cohort (GNC) [50], which is being conducted in 18 study centres, will also provide valuable point estimates of the ratio of people with known and unknown diabetes.

## 4. Incidence

### 4.1 Incidence rate of known diabetes

Few estimates of incidence rates (Info box 2) are available for known diabetes from studies that were conducted over the last few decades with various designs; the results are summarised in Table 2. Overall, these estimates indicate a clear increase in the incidence rate of known diabetes since 1960.

An incidence rate of 1.2 per 1,000 person-years (py) was observed from data sourced from the GDR diabetes register for 1960 [23]. Until 1989, when the registry was closed, an increased incidence rate of 3.8 per 1,000 py was observed [22, 51]. Apart from changes in people's behaviour, the frequency of glucosuria screening activities [22] as well as changes to the diagnostic criteria used to define diabetes (Info box 4) most likely contributed to what was described as a stepwise increase in incidence rates.



*Info box 5 (continued)*

invited actually participates (e.g. there is a lower probability of participation among people with multimorbidity). Existing data sources available for secondary analysis, such as routine data within the statutory health insurance system, in contrast, include all age groups and large sample sizes, and hence permit the conduction of stratified analyses (such as by region) as well as more timely estimates of health indicators. Nevertheless, even these data do not cover the entire population (e.g. people with private health insurance or people who do not use the healthcare system are not included) [65, 78].

**There is some evidence that the rate of people newly diagnosed with diabetes (incidence rate) has increased since the 1960s.**

For the subsequent period, point estimates from regional cohort studies indicate continued increase in diabetes incidence rates [52-54]. A recent investigation based on pooled data from five regional cohort studies (Diabetes-Collaborative Research of Epidemiologic Studies, DIAB-CORE; follow-up between 1997 to 2010) found an incidence rate of 11.8 per 1,000 py among 45- to 74-year-olds [54].

Our own analyses of nationwide data from the panel of adults who participated in two subsequent RKI health examination surveys with an average follow-up time of 12 years (follow-up period: 1997-1999 to 2008-2011) revealed an incidence rate of known diabetes of 6.9 per 1,000 py among people aged 18 to 79 years at baseline and 11.4 per 1,000 py among people aged 45 to 79 years at baseline. Based on current population estimates [55] this amounts to an estimate of about 442,000 new cases of known diabetes occurring annually among 18- to 79-year-olds in Germany. Based on routine data that are made available for research in accordance with the Data Transparency Regulation (Info box 5), a recent nationwide study has provided estimates of the type 2 diabetes incidence rate among persons 40 years and older within the German statutory health insurance system. Incidence rates amounted to 13 per 1,000 py among women and 16 per 1,000 py among men. These rates were calculated using a differential equation that took the following variables into account: 1) the prevalence of known diabetes among people with statutory health insurance between 2009 and 2010, 2) mortality rates for the general population in Germany as obtained from official statistics, and 3) the ratio of mortality rates

among people with and without diabetes based on estimates available from the neighbouring country of Denmark [39]. A further nationwide analysis of routine data available within the German statutory health insurance system was carried out by the Central Research Institute of Ambulatory Health Care in Germany (Info box 5). Among persons 40 years and older, these authors found a slight decrease in the cumulative incidence (Info box 2) of type 2 diabetes from 1.63% in 2012 to 1.47% in 2014. Calculations of the proportion of new cases within a given year were based on the requirement of a three-year pre-observation period during which the participants had received no medical diagnosis of diabetes [40].

Continuous monitoring of incidence rates of known diabetes among the general adult population in Germany at the national level, such as through continued follow-up of RKI health survey participants, is currently not being realised. However, using available routine data provides a feasible approach to obtain estimates of the cumulative incidence on a regular basis [40]. It would also be possible to use available data for continuous calculations of incidence rates using the known mathematical relationships between prevalence, incidence and mortality [39]. Country-wide estimates on the prevalence of known diabetes are available on a regular basis using data collected within the RKI Health Monitoring framework and from the routine data sources of the statutory health insurance system. Regular estimates of the mortality rate among the general population are made available by official cause-of-death statistics. Data on the ratio of mortality rates among people

**Table 1**  
**Studies providing data on the prevalence of unknown diabetes among adults in Germany**

Study population	Study period	Definition of unknown diabetes	Prevalence	Reference time point*
<b>Nationwide surveys</b>				
DEGS1: 18-79-year-olds; N=7,017 [49]	2008-2011	HbA <sub>1c</sub> ≥6.5% (Women: 1.2%; Men: 2.9%)	Total: 2.0%	31 Dec 2010
GNHIES98: 18-79-year-olds; N=6,655 [49]	1997-1999	HbA <sub>1c</sub> ≥6.5% (Women: 3.2%; Men: 4.3%)	Total: 3.8%	31 Dec 2010
GNHIES98: 18-79-year-olds; N=5,275 [29]	1997-1999	HbA <sub>1c</sub> >6.1% and either serum glucose ≥126mg/dl or glucose in urine ≥50mg/dl	Total: 3.4% Women: 2.0%; Men: 2.1%	31 Dec 1997
<b>Regional studies</b>				
KORA F4 (Augsburg): 35-79-year-olds; N=2,617;	KORA: 2006-2008	Fasting glucose ≥7.0mmol/l or 2h-OGTT glucose ≥11.1mmol/l	KORA: 3.9%	31 Dec 2007
SHIP-TREND (Vorpommern): 35-79-year-olds; N=1,980 [48]	SHIP: 2008-2012		SHIP: 7.1%	
KORA F4 (Augsburg): 35-59-year-olds; N=1,653 [47]	2006-2008	Fasting glucose ≥7.0mmol/l or 2h-OGTT glucose ≥11.1mmol/l	Total: 2.0% (Women: 1.6%; Men: 2.4%)	31 Dec 2007
Screening participants in routine health examinations of BASF employees: ≈16-64-year-olds; N=13,086 [106]	2004-2005	Fasting glucose ≥7.0 mmol/l or random glucose ≥11.1mmol/l	Total: 0.7%	
Screening participants of a sample of people insured by Techniker Krankenkasse (Thüringen, Düsseldorf) ≥55-year-olds; N=4,314 [107]	2003	Physician-diagnosed 'manifest diabetes mellitus type 2' and no self-report of diabetes diagnosis	Total: 2.8%	
HNR (Essen, Bochum, Mülheim): 45-74-year-olds; N=4,595 [108]	2000-2003	Fasting glucose ≥7.0mmol/l or random glucose ≥11.0mmol/l	Women: 3.2%; Men: 7.6%	
KORA S4 (Augsburg): 55-74-year-olds; N=1,353 [98]	1999-2001	Fasting glucose ≥7.0mmol/l or 2h-OGTT glucose ≥11.1 mmol/l	Total: 8.2% (Women: 6.9%; Men: 9.3%)	31 Dec 2000
EPIC-Potsdam: 35-59-year-olds; N≈27,500 [16]	1994-1998	Fasting or random glucose	Women: 0.4%; Men: 1.0%	2007
Sample of randomly selected cities/rural districts in 5 federal states in Germany: 18-70-year-olds; N=2,150 [99]	1993-1996	HbA <sub>1c</sub> >6.0%	Total: 1.6%	
Diabetes screening programme in Munich: All ages, N=789,289 [25]	1967/1968	Urine test strip discolouration and medical confirmation in follow-up examination	Total: about 0.7-1.1%	

\* for age-standardisation

Continued on next page

Abbreviations:

GNHIES98	German National Health Interview and Examination Survey 1998
DEGS1	German Health Interview and Examination Survey for Adults
EPIC	European Prospective Investigation into Cancer and Nutrition
HNR	Heinz Nixdorf Recall Study
HbA <sub>1c</sub>	glycated haemoglobin
KORA	Cooperative Health Research in the Region of Augsburg
OGTT	oral glucose tolerance test
SHIP	Study of Health in Pomerania

**Table 1 (continued)**  
**Studies providing data on the prevalence of unknown diabetes among adults in Germany**

Study population	Study period	Definition of unknown diabetes	Prevalence	Reference time point*
Diabetes screening programme of employees of administrations and of a pharmaceutical-chemical company (West Berlin) 16–65-year-olds, N=4,187 [109]	1965/1966	2h-OGTT glucose $\geq 7.8$ mmol/l during screening and 'manifest unknown diabetes' in follow-up examination	Total: 1.0%	
Serial examination of the population of the town of Herrenberg: all ages, N=7,976 [24]	1964	Urine test strips with glucosuria $>0.5\%$ or urine test strips with glucosuria $>0.5\%$ plus medical confirmation in follow-up examination	Total: 0.6%	
Serial examination of the population in 5 areas of the district of Magdeburg: $\geq 14$ -year-olds ( $\geq 18$ -year-olds in one district), N=164,896 [41]	1964/1965	Abnormal result of urine glucose test and confirmation in follow-up examination	Total: 0.5%	
Serial examination of the population of the district of Schwerin: $\geq 14$ years (1961/1962) or $\geq 12$ years (1964/1965), N $\approx$ je 380.000 [103]	1964/1965, 1961/1962	Urine test strip discolouration and blood glucose 7.2-11.1 mmol/l 2hours after the main meal with confirmation in follow-up examination	1964/1965: 0.2% 1961/1962: 0.3%	
Serial examination of the population in 10 out of 14 areas of the districts of Neubrandenburg: 6-80-year-olds, N=318.687 [110]	1961/1962	Urine test strip discolouration and confirmation in follow-up examination	Total: 0.3%	
<b>Patient data</b>				
GEMCAS (nationwide patient sample from general practices): $\geq 18$ years, N=35.869 (N=1.511 practices) [89]	2005	Random glucose $\geq 11.1$ mmol/l or fasting glucose $\geq 7.0$ mmol/l	Total: 0.9%	2003
Diabetes screening programme of the German Medical Association of the former Federal Republic of Germany (West Germany) N=1.474.827 (N $\approx$ 25.000 doctors) [111]	1964/1965	Urinary glucose test	Total: 1.8%	

Major systematic diabetes screening activities during the 1960s are exemplarily listed in Table 1; numerous other screenings have already been summarised elsewhere [4, 19, 20, 41]. Further studies not listed in Table 1 or Figure 1 or Figure 2 provide results on the total prevalence of known and unknown diabetes [112-114].

\* for age-standardisation

Abbreviations:

GEMCAS German Metabolic and Cardiovascular Risk Project

OGTT oral glucose tolerance test

**Table 2**  
Studies providing data on the incidence of diabetes among adults in Germany

Study population	Follow-up period*	Definition of diabetes incidence at follow-up	Incidence per 1,000 person-years	Method for consideration of bias
<b>Nationwide surveys</b>				
GNHIES98 re-participants: 18-79-year-olds, N=3.779 (own calculation)	1997-1999, 2008-2011	Self-report of physician-diagnosed diabetes or of anti-diabetic medication for the first time	<b>Known diabetes</b> 18-79-year-olds: 6.9 (Women: 7.4; Men: 6.3) 45-79-year-olds: 11.4 (Women: 10.9; Men: 12.0)	Weighting for loss of non-returnees to follow-up; standardised to population structure of Germany as of 31 Dec 1997
GNHIES98 re-participants with an examination: 18-79-year-olds, N=2.750 (own calculation)		Self-report of physician-diagnosed diabetes or of anti-diabetic medication for the first time or HbA <sub>1c</sub> ≥6.5% for the first time	<b>Known or unknown diabetes</b> 18-79-year-olds: 7.9 (Women: 9.0; Men: 6.8) 45-79-year-olds: 12.8 (Women: 12.4; Men: 13.3)	
<b>Register data</b>				
GDR diabetes register: all ages, entire population [23, 51]	Each year (reporting date 31 Dec)	Physician-diagnosed diabetes for the first time	<b>Known diabetes</b> 1989: 3.8 1960: 1.2	
GDR diabetes register, district of Neubrandenburg: all ages, entire population [115]	between 1960 and 1089		<b>Known diabetes</b> 1980: 3.4 (Women: 2.2; Men: 4.5) 1976: 3.4 (Women: 2.4; Men: 4.3) 1972: 2.5 (Women: 1.9; Men: 3.4) 1970: 2.5 (Women: 2.0; Men: 3.0) 1964: 1.2 (Women: 0.9; Men: 1.5) 1960: 0.8 (Women: 0.5; Men: 1.0)	
<b>Regional studies</b>				
DIAB-CORE Consortium with SHIP (Western Pomerania), CARLA (Halle/Saale), DHS (Dortmund), HNR (Essen, Bochum, Mülheim), KORA (Augsburg): 45-74-year-olds	N=8,787 [54]	SHIP: 1997-2001, 2002-2006 CARLA: 2002-2006, 2007-2010 DHS: 2003-2004, 2006-2008 HNR: 2000-2003, 2006-2008 KORA: 1999-2001, 2006-2008	Self-report of physician-diagnosed diabetes for the first-time  SHIP: 13.0 (Women: 10.0; Men: 16.3) CARLA: 16.2 (Women: 11.7; Men: 21.9) DHS: 16.2 (Women: 15.0; Men: 17.8) HNR: 11.8 (Women: 8.6; Men: 15.3) KORA: 9.0 (Women: 7.2; Men: 11.1)	Weighting for loss of non-returnees to follow-up; standardised to population structure of Germany as of 31 Dec 2007
	N=7,250 [116]		<b>Known diabetes</b> Total: 12.6 (Women: 9.2; Men: 16.1)	

\* Baseline – follow-up

Continued on next page

Abbreviations:  
GNHIES98 German National Health Interview and Examination Survey 1998  
GDR German Democratic Republic  
DIAB-CORE Diabetes-Collaborative Research of Epidemiologic Studies  
SHIP Study of Health in Pomerania  
CARLA Cardiovascular Disease, Living and Ageing in Halle  
DHS Dortmund Health Study  
HNR Heinz Nixdorf Recall Study  
KORA Kooperative Health Research in the Region of Augsburg  
HbA<sub>1c</sub> glycated haemoglobin

**Table 2 (continued)**  
**Studies providing data on the incidence of diabetes among adults in Germany**

Study population	Follow-up period*	Definition of diabetes incidence at follow-up	Incidence per 1,000 person-years	Method for consideration of bias
KORA S4/F4 (Augsburg): 55-74-year-olds, N=887 [58]	1999-2001, 2006-2008	Medically verified diabetes diagnosis after self-report of diabetes diagnosis for the first time or fasting glucose $\geq 7.0$ mmol/l or 2h-OGTT glucose $\geq 11.1$ mmol/l for the first time	<b>Known or unknown diabetes</b> Total: 15.5 (Women: 11.3; Men: 20.2)	Standardised to population structure of Germany as of 31 Dec 2007
SHIP (Western Pomerania): 20-79-year-olds, N=2,841; DETECT (nationwide sample of patients from general practices): $\geq 18$ -year-olds, N=4,936 [59]	SHIP: 1997-2001, 2003-2006 DETECT: 2003, 2007-2008	Self-report of diabetes diagnosis or of anti-diabetic medication for the first time or HbA <sub>1c</sub> $\geq 6.5\%$ for the first time	<b>Known or unknown diabetes</b> Total: 14.4	
EPIC-Potsdam: 35-65-year-olds, N=27,067 [53]	1994-1998, 2005	Medically verified diabetes diagnosis after self-report of diabetes diagnosis or diabetes therapy for the first time	<b>Known diabetes</b> Total: 4.8	
MONICA Augsburg: 35-74-year-olds, N=6,166 [52]	1984-1995, 1998	Self-report of diabetes diagnosis or of anti-diabetic medication for the first time	<b>Known diabetes</b> Women: 4.0; Men: 5.8	Standardised to population structure of Germany as of 31 Dec 1989
<b>Health insurance data</b>				
Nationwide sample of insurees from all statutory health insurance funds: $\geq 40$ -year-olds [39]	2009, 2010	By differential equation calculated incidence based on the change in diabetes prevalence between 2009 and 2010 in the sample of insurees (physician-diagnosed diabetes [ICD-10 E10-E14, with the additional ICD-tag, 'G' (confirmed) in outpatient diagnoses]) and the mortality among people with and without diabetes in the Danish population	<b>Known diabetes</b> Women: 13; Men: 16	
Sample of insurees from the AOK Baden-Württemberg: all ages, N $\approx$ 3.5 million per year [34]	2007-2009, the next year	Physician-diagnosed type 2 diabetes for the first time (ICD-10 E11, E12 or E14 in $\geq 3$ of 4 quarters) or prescription of anti-diabetic medication for the first-time (ATC A10A or A10B $\geq 2$ per year or 1 per year plus type 2 diabetes diagnosis or plus glucose or HbA <sub>1c</sub> measurement in the same quarter)	<b>Known diabetes</b> 2010: 8.6 (Women: 8.3; Men: 9.2) 2009: 7.7 (Women: 7.3; Men: 8.3) 2008: 8.2 (Women: 7.8; Men: 8.9)	Standardised to population structure of Baden-Württemberg as of 31 Dec of the respective year
Nationwide sample of insurees from the Techniker Krankenkasse: all ages, N=5,4 million [86]	2006-2007, 2008	Inpatient type 2 diabetes diagnosis for the first time (ICD-10 E11 with additional ICD-tag 'G' (confirmed)) or two outpatient type 2 diabetes diagnoses in different quarters of 2008 or in/before 2008	<b>Known diabetes</b> Total: 4.1	Standardised to population structure of Germany as of 31 Dec 2008

\* Baseline – follow-up

Continued on next page

Abbreviations:

AOK	Allgemeine Ortskrankenkasse (a large statutory health insurance company)
ATC	Anatomical Therapeutic Chemical Classification
DETECT	Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment
EPIC	European Prospective Investigation into Cancer and Nutrition
ICD-10	International statistical classification of diseases and related health problems, 10 <sup>th</sup> revision
KORA	Cooperative Health Research in the Region of Augsburg
MONICA	Monitoring Trends and Determinants in Cardiovascular Disease
OGTT	oral glucose tolerance test
SHIP	Study of Health in Pomerania
HbA <sub>1c</sub>	glycated haemoglobin



**Table 2 (continued)**  
Studies providing data on the incidence of diabetes among adults in Germany

Study population	Follow-up period*	Definition of diabetes incidence at follow-up	Incidence per 1,000 person-years	Method for consideration of bias
<b>Patient data</b>				
SESAM 2 (patient sample from general practices in Saxony): 2-102-year-olds, N=8,877 (N=270 practices) [95]	10/1999-09/2000	Physician-diagnosed diabetes for the first time	<b>Known diabetes</b> Total: 3.0	

Further studies not listed in Table 2 provide cumulative incidences (percentages) [40, 84] or incidence rates (per 1,000 person-years) for subgroups of individuals with normal or impaired glucose metabolism [117].

\* Baseline – follow-up

Abbreviations:

SESAM Sächsische Epidemiologische Studien in der Allgemeinmedizin

with and without known diabetes, which has been ‘borrowed’ from the neighbouring country of Denmark until now, could be frequently made available also for Germany if follow-up of RKI health survey participants for vital status (mortality follow-up) could be conducted on a regular basis [56, 57].

#### 4.2 Overall incidence of unknown and known diabetes overall

The incidence rate of unknown and known diabetes combined has only recently been estimated by a number of studies. However, results from these studies are difficult to compare due to differences in study design, age range and reference region (Table 2).

Based on KORA S4/F4 cohort data (follow-up period: 1999-2001 to 2006-2008), the incidence rate for known diabetes and unknown diabetes (defined using fasting blood glucose level and 2h-OGTT glucose) combined was estimated to be 15.5 per 1,000 py among 55- to 79-year-olds from the Augsburg area [58]. A comprehensive analysis of data from the SHIP cohort in Western Pomerania (follow-up period: 1997-2001 to 2003-2006;

20- to 79-year-olds) and a nationwide sample of patient data (Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment, DETECT; follow-up period: 2003 to 2007/2008; people aged 18 years or above) revealed an incidence rate for known and (HbA<sub>1c</sub>-defined) unknown diabetes of 14.4 per 1,000 py [59]. Our own analyses of nationwide data from adults who participated in two RKI examination surveys spaced approximately 12 years apart (follow-up period: 1997-1999 to 2008-2011) resulted in an incidence rate of known and (HbA<sub>1c</sub>-defined) unknown diabetes of 7.9 per 1,000 py among persons aged 18 to 79 years at baseline and a rate of 12.8 per 1,000 py among those aged 45 to 79 years at baseline. Based on current population statistics in Germany [55], this corresponds to approximately 507,000 new cases of diabetes per year in the population 18 to 79 years of age.

Currently available data do not permit estimation of time trends in overall diabetes incidence rates among adults in Germany. In the future, the total incidence rate could be calculated using the differential equation mentioned above [39]. For this, estimates of the prevalence of known and unknown diabetes will be available, albeit

**Currently available data do not permit estimation of time trends in the prevalence and incidence of unknown diabetes.**

**Table 3**  
Studies providing data on overall mortality among adults with diabetes compared to adults without diabetes in Germany

Study population	Follow-up period <sup>1</sup>	Definition of diabetes and reference group at baseline	Mortality among adults with diabetes compared to the reference group		Methods to account for bias		
			Crude <sup>2</sup> mortality rate <sup>3</sup>	Age-adjusted hazard ratio <sup>4</sup>			
<b>Nationwide surveys</b>							
GNHIES98 Mortality Follow-up: 18-79-year-olds, N=6,299 [57]	1997-1999, 2008-2011	<b>Known diabetes:</b> Self-report of physician-diagnosed diabetes or of anti-diabetic medication		27.4	1.7	Follow-up for vital status completed for 98%; Adjusted for age, sex	
		<b>Unknown diabetes:</b> HbA <sub>1c</sub> ≥6.5%		29.4	1.9		
		<b>Prediabetes:</b> HbA <sub>1c</sub> : 5.7-5.9%/6.0-6.4%		11.3/8.6	1.0/1.0		
		Reference: No known or unknown (pre-) diabetes		4.1	1 (reference)		
<b>Register data</b>							
GDR diabetes register: all ages, All people with known diabetes (compared to the general population) [60]	Each year between 1961 and 1987	<b>Known diabetes:</b> Physician-diagnosed diabetes; Reference: general population	Non-insulin-dependent diabetes	1961: ≈47 1987: ≈67	–	Follow-up for vital status completed for nearly 100%; Standardised to age structure of the general population	
			Insulin-dependent diabetes	1961: ≈64 1987: ≈77	–		
			Total diabetes	–	1961: 1.9 1987: 1.7		
<b>Regional studies</b>							
ERFORT (Erfurt area): 40-59-year-olds, N=1,125 men [61]	1973-1975, 2003	<b>Known diabetes:</b> Self-report of physician-diagnosed diabetes	10 years	21.5	2.2	Follow-up for vital status completed for 98%; Adjusted for age	
			20 years	38.1	2.2		
			30 years	43.1	1.9		
			<b>Unknown diabetes:</b> 1h-OGTT glucose ≥200 mg/dl	10 years	17.0		1.8
			20 years	24.5	1.5		
30 years	31.5	1.5					
Reference: No known or unknown diabetes	10 years	8.0	1				
	20 years	15.4	(reference)				
	30 years	20.6					

Continued on next page

## Abbreviations:

GNHIES98	German National Health Interview and Examination Survey 1998
GDR	German Democratic Republic
ERFORT	Erfurt Male Cohort Study
HbA <sub>1c</sub>	glycated haemoglobin
OGTT	oral glucose tolerance test

- <sup>1</sup> Baseline – follow-up  
<sup>2</sup> not age-adjusted or age-standardised  
<sup>3</sup> per 1,000 person-years  
<sup>4</sup> or age-standardised mortality ratio

**Table 3 (continued)**  
**Studies providing data on overall mortality among adults with diabetes compared to adults without diabetes in Germany**

Study population	Follow-up period <sup>1</sup>	Definition of diabetes and reference group at baseline	Mortality among adults with diabetes compared to the reference group		Methods to account for bias
			Crude <sup>2</sup> mortality rate <sup>3</sup>	Age-adjusted hazard ratio <sup>4</sup>	
KORA S4 (Augsburg area): 55-74-year-olds, N=1,466 [62]	1999-2001, 2008-2009	<b>Known Diabetes:</b> Verified self-report of physician-diagnosed diabetes	30.7	2.6	Follow-up for vital status completed for 99%; Adjusted for age, sex
		<b>Unknown diabetes:</b> Fasting glucose $\geq 7.0$ mmol/l or 2h-OGTT glucose $\geq 11.1$ mmol/l	35.4	2.8	
		<b>Prediabetes:</b> Fasting glucose 6.1-6.9 mmol/l or 2h-OGTT glucose 7.8-11.0 mmol/l	13.3	1.1	
		Reference: No known or unknown (pre-) diabetes	10.5	1 (reference)	
<b>Patient data</b>					
Erfurt-Study (district of Erfurt): all ages, N=208 people with diabetes (compared to N=208 paired controls) [118]	1970, 1985	<b>Known diabetes:</b> History of physician-diagnosed diabetes of $\geq 20$ years; Reference: paired metabolically healthy people		2.1	Follow-up for vital status completed for 93%; Case-control pairing according to age, sex, body weight

A further study, which is not listed in Table 3, exclusively provides age- and gender-specific mortality ratios [102].

- <sup>1</sup> Baseline – follow-up  
<sup>2</sup> not age-adjusted or age-standardised  
<sup>3</sup> per 1,000 person-years  
<sup>4</sup> or age-standardised mortality ratio

at larger intervals, from the national RKI health examination surveys [49]. Moreover, continued mortality follow-up of RKI health survey participants would permit periodically repeated estimates of mortality rates among people with and without known or unknown diabetes [56, 57]. In addition, ongoing cohort studies in Germany will continue to contribute point estimates of overall diabetes incidence.

## 5. Mortality

### 5.1 Mortality among people with known diabetes

Only a small number of studies have provided data on diabetes-related excess mortality (Table 3), in other words, the mortality rate of people with diabetes compared to the general population or people without diabetes (Info box 3). Results from these studies show that

#### Abbreviations:

KORA Cooperative Health Research in the Region of Augsburg  
 OGTT oral glucose tolerance test

**There is evidence that the risk of death among people with known diabetes is about twice as high as among people without the condition; the increased risk of death (excess mortality) among people with unknown diabetes appears to be about as high as among people with known diabetes.**

mortality rates among people with diabetes have decreased over recent decades. However, the results also suggest that mortality rates among people with diabetes remain higher than among people of the same age who do not have diabetes.

According to early estimates based on data from the GDR diabetes register, the ratio of age-standardised mortality rates among people with known diabetes compared to the general population slightly declined from 1.9 in 1961 to 1.7 in 1987, although this decrease was not statistically significant [60].

More recently, the Erfurt Male Cohort Study (ERFORT study; follow-up period: 1973-1975 to 2003) demonstrated a 1.9-fold higher risk of death from all causes among 40- to 59-year-old men with known diabetes [61], the KORA S4 study (follow-up period: 1999-2001 to 2008/2009) identified a 2.6-fold higher risk among 55- to 74-year-olds [62]; and the GNHIES98 (follow-up period: 1997-1999 to 2008-2011) found a 1.7-fold higher risk of mortality among 18- to 79-year-olds [57]. Each study compared age-adjusted mortality rates among people with known diabetes to people without known or unknown diabetes.

Official statistics on causes of death provided by the Federal Statistical Office provide data for monitoring mortality rates in the general population (of 100,000 inhabitants) [63]. However, the mortality follow-up of persons participating in the national RKI health examination surveys is currently the only nationwide data source that can be used to calculate population-based mortality rates among adults with diabetes compared to those without diabetes [56, 57]. It would therefore be

important to continue the follow-up of survey participants' vital statistics (so far running for GNHIES98 and DEGS1). Looking forward, the mortality follow-up of people participating in the on-going German National Cohort [50] as well as mortality data that will be available for secondary analysis of existing data from the statutory health insurance system will also provide information about diabetes-related excess mortality.

### 5.2 Mortality among people with unknown diabetes

The only estimates of excess mortality among people with unknown diabetes that currently exist are from the three follow-up studies mentioned in the last section (Table 3). Therefore, it is currently impossible to estimate time trends in this regard.

The ERFORT study found that the risk of death among people with unknown diabetes was 1.5 times higher compared to people without diabetes [61]. The KORA S4 study identified the rate as 2.8 times higher [62] and the GNHIES98 study found a rate that was 1.9 times higher [57]. Thus, the risk of death among people with unknown diabetes is of a similar magnitude as the risk of death observed among people with known diabetes. In contrast, the studies found no increased risk of death among people with 'prediabetes' [57, 62] (Table 3).

The continuation of the mortality follow-up of people participating in the national RKI health examination surveys, therefore, would also be useful in order to gain regular estimates (albeit at larger intervals) of the excess mortality linked to unknown diabetes and diabetes overall [56, 57]. In addition, following up the vital statistics

**Data on key measures (core indicators) of diabetes epidemiology in Germany is yet limited, but will be expanded and consolidated within the framework of the German National Diabetes Surveillance System.**

of participants from ongoing cohort studies could provide point estimates of excess mortality related to unknown diabetes.

## 6. Conclusion

Population-based estimates of the prevalence, incidence and excess mortality of known and unknown diabetes are key indicators in order to conduct a reliable evaluation of developments in diabetes epidemiology. Providing regular estimates of these indicators that are comparable over time, therefore, is a major goal of the national diabetes surveillance system that is currently being established in Germany. With the exception of the prevalence of known diabetes (where regularly collected primary and secondary data demonstrate an increase over the last few decades), the data being collected on these key indicators of diabetes epidemiology in Germany is currently fragmented. Estimates of incidence rates and the excess mortality associated with known diabetes that are currently available, mainly from cohort studies, only enable cautious conclusions to be drawn on time trends. Estimates of the prevalence, incidence and mortality of unknown diabetes in Germany are scarce and do not permit the evaluation of time trends.

An expansion of existing approaches is therefore needed in order to resolve the current issues with the data. Thus, the regular continuation of the mortality follow-up of people taking part in the RKI national health examination surveys would permit monitoring of the mortality rates among people with diabetes compared to those without the condition, albeit at larger intervals.

This could reduce the large gaps that exist in recurrent estimates of excess mortality in relation to both known and unknown diabetes. As demonstrated by recent studies, improved access to secondary analysis of existing data would help produce more timely estimates of the prevalence, as well as the incidence of known diabetes. Routine data available within the statutory health insurance system are of particular importance in this respect. While these routine data sources cover most of the population, certain groups of people (for example, people insured by private health insurers) are not represented in the sample. Moreover, indicators calculated based on routine data will be limited to known diabetes. The use of mathematical equations could therefore be considered as a further means of closing existing gaps in the data. As an example, population-based incidence rates of known and unknown diabetes could be derived from the mathematical relationships between the data on diabetes prevalence and excess mortality provided by the national RKI health examination surveys.

A national diabetes surveillance system is currently being established at the RKI. The various approaches and available data sources are currently being assessed with regard to their availability and whether they can be integrated into a continuous monitoring of dynamics in diabetes epidemiology as a means of providing a data-supported foundation for health policy decision-making in Germany [64, 65]. Taking into account demographic trends, a foundation could also be used for projections of burden of disease.



## References

1. Zaccardi F, Webb DR, Yates T et al. (2016) Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgrad Med J* 92(1084):63-69
2. van Dieren S, Beulens JW, van der Schouw YT et al. (2010) The global burden of diabetes and its complications: an emerging pandemic. *Eur J Cardiovasc Prev Rehabil* 17 Suppl 1:S3-8
3. Polonsky KS (2012) The past 200 years in diabetes. *N Engl J Med* 367(14):1332-1340
4. Schliack V (1971) Die Verbreitung des Diabetes mellitus: Häufigkeit und Vorkommen in Europa und Amerika In: Pfeiffer EF (eds) *Pathophysiologie und Klinik*. Springer-Verlag Berlin Heidelberg, P. 333-364
5. Rostski O (1958) Über die Zunahme der Zuckerkranken. *Munch Med Wochenschr* 100(9):342-346
6. Kaeding A (1964) Die Verbreitung des Diabetes mellitus in Deutschland. *Der Diabetiker* 14(4):107-112
7. NCD Risk Factor Collaboration (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 387(10027):1513-1530
8. Editorial (2011) The diabetes pandemic. *Lancet* 378(9786):99
9. Hu FB, Satija A, Manson JE (2015) Curbing the Diabetes Pandemic: The Need for Global Policy Solutions. *JAMA* 313(23):2319-2320
10. International Diabetes Federation (2015) *IDF Diabetes Atlas, 7th edn*. Chapter 3 The global picture. Brussels, Belgium. <http://www.diabetesatlas.org/> (As at 19.12.2016)
11. Porta M, Curletto G, Cipullo D et al. (2014) Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. *Diabetes Care* 37(6):1668-1674
12. Spijkerman AM, Dekker JM, Nijpels G et al. (2003) Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. *Diabetes Care* 26(9):2604-2608
13. Koopman RJ, Mainous AG, 3rd, Liszka HA et al. (2006) Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. *Ann Fam Med* 4(5):427-432
14. Harris MI (1993) Undiagnosed NIDDM: clinical and public health issues. *Diabetes Care* 16(4):642-652
15. Wareham NJ, Forouhi NG (2005) Is there really an epidemic of diabetes? *Diabetologia* 48(8):1454-1455
16. Schulze MB, Rathmann W, Giani G et al. (2010) Diabetesprävalenz - Verlässliche Daten stehen noch aus. *Dtsch Arztebl* 107(36):A 1694-1696
17. Tamayo T, Rosenbauer J, Wild SH et al. (2014) Diabetes in Europe: an update. *Diabetes Res Clin Pract* 103(2):206-217
18. Zimmet P, Alberti KG, Magliano DJ et al. (2016) Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. *Nat Rev Endocrinol* 12(10):616-622
19. Schliack V (1965) Über die Diabetes-Morbidität. *Dtsch Med Wochenschr* 90(52):2321-2327
20. von Knorre G (1964) Ergebnisse einer Diabetes-Reihenuntersuchung in einem Landkreis 1961/1962. *Dtsch Ges Wes* 19:593-598
21. Schliack V (1980) Zur Diabetesmorbidität unter besonderer Berücksichtigung der DDR sowie zur Krankheitsprognose. *Z Arztl Fortbild (Jena)* 74(13-14):668-670
22. Michaelis D, Jutzi E, Albrecht G (1987) Prevalence and incidence trends of non-insulin-dependent diabetes mellitus (NIDDM) in the population of the GDR. *Dtsch Z Verdau Stoffwechsellkr* 47(6):301-310
23. Michaelis D, Jutzi E (1991) Epidemiologie des Diabetes mellitus in der Bevölkerung der ehemaligen DDR: Alters- und geschlechtsspezifische Inzidenz- und Prävalenztrends im Zeitraum 1960-1987. *Z Klin Med* 46:59-64
24. Glogner P, Duerr F (1964) Suchaktion auf Diabetes und Nephropathien. *Dtsch Med Wochenschr* 89:2081-2083
25. Mehnert H, Sewering H, Reichstein W et al. (1968) Früherfassung von Diabetikern in München 1967-68. *Dtsch Med Wochenschr* 93(43):2044-2050
26. Helmert U, Janka HU, Strube H (1994) Epidemiologische Befunde zur Häufigkeit des Diabetes mellitus in der Bundesrepublik Deutschland 1984 bis 1991. *Diab Stoffw* 3:271-277
27. Hauner H, von Ferber L, Koster I (1992) Schätzung der Diabeteshäufigkeit in der Bundesrepublik Deutschland anhand von Krankenkassendaten. Sekundärdatenanalyse einer repräsentativen Stichprobe AOK-Versicherter der Stadt Dortmund. *Dtsch Med Wochenschr* 117(17):645-650
28. Meisinger C, Heier M, Doering A et al. (2004) Prevalence of known diabetes and antidiabetic therapy between 1984/1985 and 1999/2001 in southern Germany. *Diabetes Care* 27(12):2985-2987

29. Thefeld W (1999) Prävalenz des Diabetes mellitus in der erwachsenen Bevölkerung Deutschlands. *Gesundheitswesen* 61 Spec No:S85-89
30. Heidemann C, Kroll L, Icks A et al. (2009) Prevalence of known diabetes in German adults aged 25-69 years: results from national health surveys over 15 years. *Diabet Med* 26(6):655-658
31. Heidemann C, Du Y, Schubert I et al. (2013) Prevalence and temporal trend of known diabetes mellitus: results of the German Health Interview and Examination Survey for Adults (DEGS1). *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitschutz* 56(5-6):668-677  
<http://edoc.rki.de/oa/articles/re8zBK9JuD8n2/PDF/29RbpZ8k-viL4c.pdf> (As at 01.03.2017)
32. Heidemann C, Du Y, Scheidt-Nave C (2011) Diabetes mellitus in Germany. *GBE kompakt* 2(3):1-7. Robert-Koch-Institut, Berlin.  
<http://edoc.rki.de/series/gbe-kompakt/2-3/PDF/3.pdf> (As at 01.03.2017)
33. Hoffmann F, Icks A (2011) Diabetes prevalence based on health insurance claims: large differences between companies. *Diabetic Medicine* 28(8):919-923
34. Boehme MW, Buechele G, Frankenhauser-Mannuss J et al. (2015) Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in South Western Germany—a retrospective cohort and case control study in claims data of a large statutory health insurance. *BMC Public Health* 15:855
35. Koster I, Schubert I, Huppertz E (2012) Fortschreibung der KoDiM-Studie: Kosten des Diabetes mellitus 2000-2009. *Dtsch Med Wochenschr* 137(19):1013-1016
36. Du Y, Heidemann C, Schaffrath Rosario A et al. (2015) Changes in diabetes care indicators: findings from German National Health Interview and Examination Surveys 1997-1999 and 2008-2011. *BMJ Open Diabetes Res Care* 3(1):e000135
37. Fuchs S, Henschke C, Blumel M et al. (2014) Disease management programs for type 2 diabetes in Germany: a systematic literature review evaluating effectiveness. *Dtsch Arztebl Int* 111(26):453-463
38. Paprott R, Mensink GBM, Schulze MB et al. (2017) Temporal changes in predicted risk of type 2 diabetes in Germany: findings from the German Health Interview and Examination Surveys 1997-1999 and 2008-2011. *BMJ Open* 7(7):e013058
39. Tamayo T, Brinks R, Hoyer A et al. (2016) The Prevalence and Incidence of Diabetes in Germany. *Dtsch Arztebl Int* 113(11):177-182
40. Goffrier B, Schulz M, Bätzing-Feigenbaum J (2017) Administrative Prävalenzen und Inzidenzen des Diabetes mellitus von 2009 bis 2015. *Versorgungsatlas-Bericht Nr 17/03:1-35*. Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi), Berlin.  
[http://www.versorgungsatlas.de/fileadmin/ziva\\_docs/79/VA-79-Bericht\\_Final.pdf](http://www.versorgungsatlas.de/fileadmin/ziva_docs/79/VA-79-Bericht_Final.pdf) (As at 07.09.2017)
41. Apel H, Beier W, Berbig G et al. (1967) Reihenuntersuchungen auf Diabetes mellitus im Bezirk Magdeburg 1964-65. *Z Arztl Fortbild (Jena)* 61(12):633-637
42. Schliack V (1963) Empfehlungen zur Durchführung von Diabetes-Suchaktionen. *Dtsch Ges Wes*:230-232
43. Schneider H, Ehrlich M, Lischinski M et al. (1996) Bewirkte das flächendeckende Glukosurie-Screening der 60er und 70er Jahre im Osten Deutschlands tatsächlich den erhofften Prognosevorteil für die frühzeitig entdeckten Diabetiker? *Diab Stoffw* 5:33-38
44. Herron CA (1979) Screening in diabetes mellitus: report of the Atlanta workshop. *Diabetes Care* 2(4):357-362
45. Bennett CM, Guo M, Dharmage SC (2007) HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. *Diabet Med* 24(4):333-343
46. NCD Risk Factor Collaboration (2015) Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. *Lancet Diabetes Endocrinol* 3(8):624-637
47. Meisinger C, Strassburger K, Heier M et al. (2010) Prevalence of undiagnosed diabetes and impaired glucose regulation in 35-59-year-old individuals in Southern Germany: the KORA F4 Study. *Diabet Med* 27(3):360-362
48. Tamayo T, Schipf S, Meisinger C et al. (2014) Regional differences of undiagnosed type 2 diabetes and prediabetes prevalence are not explained by known risk factors. *PLoS One* 9(11):e113154
49. Heidemann C, Du Y, Paprott R et al. (2016) Temporal changes in the prevalence of diagnosed diabetes, undiagnosed diabetes and prediabetes: findings from the German Health Interview and Examination Surveys in 1997-1999 and 2008-2011. *Diabet Med* 33(10):1406-1414
50. German National Cohort Consortium (2014) The German National Cohort: aims, study design and organization. *Eur J Epidemiol* 29(5):371-382
51. Michaelis D, Jutzi E, Vogt L (1993) Epidemiology of insulin-treated diabetes mellitus in the East-German population: differences

- in long-term trends between incidence and prevalence rates. *Diabetes Metab* 19(1 Pt 2):110-115
52. Meisinger C, Thorand B, Schneider A et al. (2002) Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. *Arch Intern Med* 162(1):82-89
  53. Schulze MB, Schulz M, Heidemann C et al. (2008) Carbohydrate intake and incidence of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. *Br J Nutr* 99(5):1107-1116
  54. Schipf S, Ittermann T, Tamayo T et al. (2014) Regional differences in the incidence of self-reported type 2 diabetes in Germany: results from five population-based studies in Germany (DIAB-CORE Consortium). *J Epidemiol Community Health* 68(11):1088-1095
  55. Statistisches Bundesamt (2017) Bevölkerungsstand. Bevölkerung: Deutschland, Stichtag, Altersjahre (Stichtag 31.12.2015). Ausgangsdaten der Bevölkerungsforschung aus dem Zensus 2011. <http://www.gbe-bund.de> (As at 31.05.2017)
  56. Wolf IK, Busch M, Lange M et al. (2014) Mortality follow-up of the German Health Interview and Examination Survey for Adults (DEGS): methods and first results. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 57(11):1331-1337
  57. Paprott R, Schaffrath Rosario A, Busch MA et al. (2015) Association between hemoglobin A1c and all-cause mortality: results of the mortality follow-up of the German National Health Interview and Examination Survey 1998. *Diabetes Care* 38(2):249-256
  58. Rathmann W, Strassburger K, Heier M et al. (2009) Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. *Diabetic Medicine* 26(12):1212-1219
  59. Schneider HJ, Friedrich N, Klotsche J et al. (2011) Prediction of incident diabetes mellitus by baseline IGF1 levels. *Eur J Endocrinol* 164(2):223-229
  60. Michaelis D, Jutzi E (1990) Trends in mortality rates in the diabetic population of the GDR. *Exp Clin Endocrinol* 95(1):83-90
  61. Meisinger C, Wolke G, Brasche S et al. (2006) Postload plasma glucose and 30-year mortality among nondiabetic middle-aged men from the general population: the ERFORT Study. *Ann Epidemiol* 16(7):534-539
  62. Kowall B, Rathmann W, Heier M et al. (2011) Categories of glucose tolerance and continuous glycemic measures and mortality. *Eur J Epidemiol* 26(8):637-645
  63. Statistisches Bundesamt (2015) Todesurschenstatistik. Sterbefälle, Sterbeziffern (je 100000 Einwohner, altersstandardisiert) (ab 1998). <http://www.gbe-bund.de> (As at 04.04.2017)
  64. Gabrys L, Schmidt C, Heidemann C et al. (2017) Diabetes surveillance in Germany - Background, concept and prospects. *Journal of Health Monitoring* 2 (1):91-104. Robert Koch-Institut, Berlin. <http://edoc.rki.de/oa/articles/remfjF4Dma6l/PDF/24SGnU-vGo4j2.pdf> (As at 08.06.2017)
  65. Schmidt C, Batzing-Feigenbaum J, Bestmann A et al. (2017) Integration von Sekundärdaten in die Nationale Diabetes-Surveillance: Hintergrund, Ziele und Ergebnisse des Sekundärdaten-Workshops am Robert Koch-Institut. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 60(6):656-661
  66. Ressing M, Blettner M, Klug SJ (2010) Data Analysis of Epidemiological Studies: Part 11 of a Series on Evaluation of Scientific Publications. *Dtsch Arztebl Int* 107(11):187-192
  67. Gordis L (2001) *Epidemiologie: Maße der Erkrankungshäufigkeit*. Verlag im Kilian, Marburg, P. 35-71
  68. World Health Organization (1965) *Diabetes mellitus: Report of a WHO Expert Committee*. Technical Report Series 310:1-44. World Health Organization, Geneva. [http://apps.who.int/iris/bitstream/10665/38442/1/WHO\\_TRS\\_310.pdf](http://apps.who.int/iris/bitstream/10665/38442/1/WHO_TRS_310.pdf) (As at 06.06.2017)
  69. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 28(12):1039-1057
  70. World Health Organization (1980) *WHO Expert Committee on diabetes mellitus: Second report*. Technical Report Series 646:1-80. World Health Organization, Geneva. [http://apps.who.int/iris/bitstream/10665/41399/1/WHO\\_TRS\\_646.pdf](http://apps.who.int/iris/bitstream/10665/41399/1/WHO_TRS_646.pdf) (As at 06.06.2017)
  71. World Health Organization (1985) *Diabetes mellitus: Report of a WHO study group*. Technical Report Series 727:1-113. World Health Organization, Geneva. [http://apps.who.int/iris/bitstream/10665/39592/1/WHO\\_TRS\\_727.pdf](http://apps.who.int/iris/bitstream/10665/39592/1/WHO_TRS_727.pdf) (As at 06.06.2017)
  72. Genuth S, Alberti KG, Bennett P et al. (2003) Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26(11):3160-3167
  73. World Health Organization (1999) *Definition, diagnosis and classification of diabetes mellitus and its complications*. Report of a WHO conulstation. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization, Geneva.

- [http://apps.who.int/iris/bitstream/10665/66040/1/WHO\\_NCD\\_NCS\\_99.2.pdf](http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf) (As at 06.06.2017)
74. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. *Diabetes Care* 33 Suppl 1:S62-69
  75. Kerner W, Brückel J (2010) Definition, classification and diagnosis of diabetes mellitus. *Exp Clin Endocrinol Diabetes* 122(7):384-386
  76. World Health Organization (2011) Use of glycated haemoglobin (HbA<sub>1c</sub>) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation.1-25. World Health Organization, Geneva. [http://www.who.int/diabetes/publications/diagnosis\\_diabetes2011/en/](http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/) (As at 06.06.2017)
  77. Kurth BM, Lange C, Kamtsiuris P et al. (2009) Gesundheitsmonitoring am Robert Koch-Institut. Sachstand und Perspektiven. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 52(5):557-570
  78. Ohlmeier C, Frick J, Prütz F et al. (2014) Nutzungsmöglichkeiten von Routinedaten der Gesetzlichen Krankenversicherung in der Gesundheitsberichterstattung des Bundes. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 57(4):464-472
  79. Robert Koch-Institut (2014) Daten und Fakten: Ergebnisse der Studie „Gesundheit in Deutschland aktuell 2012“. Beiträge zur Gesundheitsberichterstattung des Bundes. RKI, Berlin. [http://edoc.rki.de/documents/rki\\_fv/recjuHnzacx8A/PDF/28Gs-WuNtFjVqY.pdf](http://edoc.rki.de/documents/rki_fv/recjuHnzacx8A/PDF/28Gs-WuNtFjVqY.pdf) (As at 01.11.2016)
  80. Robert Koch-Institut (2012) Daten und Fakten: Ergebnisse der Studie „Gesundheit in Deutschland aktuell 2010“. Beiträge zur Gesundheitsberichterstattung des Bundes. RKI, Berlin. [http://edoc.rki.de/documents/rki\\_fv/remDCctjOxl/PDF/21TgK-GZEOWNCY.pdf](http://edoc.rki.de/documents/rki_fv/remDCctjOxl/PDF/21TgK-GZEOWNCY.pdf) (As at 01.11.2016)
  81. Robert Koch-Institut (2010) Daten und Fakten: Ergebnisse der Studie „Gesundheit in Deutschland aktuell 2009“. Beiträge zur Gesundheitsberichterstattung des Bundes. RKI, Berlin. [http://edoc.rki.de/documents/rki\\_fv/reQXTR7OSGFRg/PDF/20dqmVRMM57G6.pdf](http://edoc.rki.de/documents/rki_fv/reQXTR7OSGFRg/PDF/20dqmVRMM57G6.pdf) (As at 01.11.2016)
  82. Hoffmann F, Icks A (2012) Diabetes 'Epidemic' in Germany? A Critical Look at Health Insurance Data Sources. *Exp Clin Endocrinol Diabetes* (EFirst)
  83. Heidemann C, Kuhnert R, Born S et al. (2017) 12-Month prevalence of known diabetes mellitus in Germany. *Journal of Health Monitoring* 2(1):48-56. Robert Koch-Institut, Berlin. <http://edoc.rki.de/oa/articles/rei427ccepm96/PDF/27H3uMDZ-mc4wQ.pdf> (As at 05.04.2017)
  84. Muller N, Heller T, Freitag MH et al. (2015) Healthcare utilization of people with type 2 diabetes in Germany: an analysis based on health insurance data. *Diabet Med* 32(7):951-957
  85. Stock SA, Redaelli M, Wendland G et al. (2006) Diabetes-prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. *Diabet Med* 23(3):299-305
  86. Wilke T, Ahrendt P, Schwartz D et al. (2013) Inzidenz und Prävalenz von Diabetes mellitus Typ 2 in Deutschland: Eine Analyse auf Basis von 5,43 Mio. Patientendaten. *Dtsch Med Wochenschr* 138(3):69-75
  87. Lehnert H, Wittchen HU, Pittrow D et al. (2005) Prävalenz und Pharmakotherapie des Diabetes mellitus in der primärärztlichen Versorgung. *Dtsch Med Wochenschr* 130(7):323-328
  88. Pittrow D, Stalla GK, Zeiher AM et al. (2006) Prävalenz, medikamentöse Behandlung und Einstellung des Diabetes mellitus in der Hausarztpraxis. *Med Klin (Munich)* 101(8):635-644
  89. Hauner H, Hanisch J, Bramlage P et al. (2008) Prevalence of undiagnosed Type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). *Exp Clin Endocrinol Diabetes* 116(1):18-25
  90. Kahl B, Pieper J, Schweikart J et al. (2017) Die räumliche Verbreitung des Typ 2 Diabetes Mellitus in Berlin - Die Anwendung einer geografisch gewichteten Regressionsanalyse zur Identifikation ortsspezifischer Risikogruppen. *Gesundheitswesen*
  91. Koster I, Huppertz E, Hauner H et al. (2014) Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001. *Exp Clin Endocrinol Diabetes* 122(9):510-516
  92. Köster I, Huppertz E, Hauner H et al. (2011) Direct Costs of Diabetes Mellitus in Germany - CoDiM 2000-2007. *Exp Clin Endocrinol Diabetes* 119(6):377-385
  93. Hauner H, Köster I, Schubert I (2007) Prevalence of Diabetes mellitus and Quality of Care in Hesse, Germany, 1998-2004. *Dtsch Arztebl* 104(41):A2799-2805
  94. Maatouk I, Wild B, Wesche D et al. (2012) Temporal predictors of health-related quality of life in elderly people with diabetes: results of a german cohort study. *PLoS One* 7(1):e31088
  95. Frese T, Sandholzer H, Voigt S et al. (2008) Epidemiology of diabetes mellitus in German general practitioners' consultation-results of the SESAM 2-study. *Exp Clin Endocrinol Diabetes* 116(6):326-328

96. Raum P, Lamparter J, Ponto KA et al. (2015) Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study. *PLoS One* 10(6):e0127188
97. Schipf S, Werner A, Tamayo T et al. (2012) Regional differences in the prevalence of known type 2 diabetes mellitus in 45-74 years old individuals: Results from six population-based studies in Germany (DIAB-CORE Consortium). *Diabet Med* 29(7):e88-95
98. Rathmann W, Haastert B, Icks A et al. (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. *Diabetologia* 46(2):182-189
99. Palitzsch K-D, Nusser J, Arndt H et al. (1999) Die Prävalenz des Diabetes mellitus wird in Deutschland deutlich unterschätzt - eine bundesweite epidemiologische Studie auf Basis einer HbA1c-Analyse. *Diab Stoffw* 8:189-200
100. Schubert A, Schneider H (1992) Zur Bestandsentwicklung des Diabetes mellitus in einer ländlichen Region des Landes Mecklenburg-Vorpommern. *Z Arztl Fortbild (Jena)* 86(23-24):1185-1189
101. Ratzmann KP (1991) Eine Analyse von alters- und geschlechtsspezifischer Diabetesprävalenz sowie Behandlungsart: Die Berlin-Studie. *Akt Endokr Stoffw* 12:220-223
102. Panzram G, Zabel-Langhennig R (1981) Prognosis of diabetes mellitus in a geographically defined population. *Diabetologia* 20(6):587-591
103. Kruger HU (1967) On the increase in morbidity of diabetes mellitus. Results of repeated serial studies in the same population during the years 1961-1962 and 1964-65 in the District of Schwerin. *Dtsch Gesundheitsw* 22(7):301-307
104. Elkeles T, Beck D, Roding D et al. (2012) Health and lifestyle in rural northeast Germany: the findings of a Rural Health Study from 1973, 1994, and 2008. *Dtsch Arztebl Int* 109(16):285-292
105. Muschik D, Tetzlaff J, Lange K et al. (2017) Change in life expectancy with type 2 diabetes: a study using claims data from lower Saxony, Germany. *Popul Health Metr* 15(1):5
106. Oberlinner C, Neumann SM, Ott MG et al. (2008) Screening for pre-diabetes and diabetes in the workplace. *Occup Med (Lond)* 58(1):41-45
107. Scherbaum WA, Dicken HD, Verheyen F et al. (2006) Nachweis eines bisher unerkannten Diabetes mellitus Typ 2 mittels Risikofragebogen. Effizienz beim allgemeinen Populations-Screening. *Dtsch Med Wochenschr* 131(40):2208-2212
108. Icks A, Kruse J, Dragano N et al. (2008) Are symptoms of depression more common in diabetes? Results from the Heinz Nixdorf Recall study. *Diabet Med* 25(11):1330-1336
109. Gutsche H (1967) Auswertung einer Diabetes-Früherkennungsaktion in Berlin. *Bundesgesundheitsblatt* 26:408-412
110. Jung HD (1963) Prophylaktische Diabetes-Reihenuntersuchung zur Aufdeckung eines unerkannten Diabetes-mellitus mittels Ferment-Teststreifen im Agrarbezirk Neubrandenburg. *Der Diabetiker* 13:47-49
111. Bundesärztekammer (1966) Diabetes-Früherkennungsaktion 1964/65. *Dtsch Arztebl* 20:1325-1327
112. Volzke H, Ittermann T, Schmidt CO et al. (2015) Prevalence trends in lifestyle-related risk factors. *Dtsch Arztebl Int* 112(11):185-192
113. Li J, Jarczok MN, Loerbroks A et al. (2013) Work stress is associated with diabetes and prediabetes: cross-sectional results from the MIPH Industrial Cohort Studies. *Int J Behav Med* 20(4):495-503
114. Buyken AE, von Eckardstein A, Schulte H et al. (2007) Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. *Eur J Cardiovasc Prev Rehabil* 14(2):230-236
115. Schubert A, Faika E (1982) Ist der Diabetes mellitus auf dem Wege zum epidemiologischen Zustand des Gleichgewichts? *Z Gesamte Inn Med* 37(22):763-767
116. Muller G, Wellmann J, Hartwig S et al. (2015) Association of neighbourhood unemployment rate with incident Type 2 diabetes mellitus in five German regions. *Diabet Med* 32(8):1017-1022
117. Schottker B, Raum E, Rothenbacher D et al. (2011) Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. *Eur J Epidemiol* 26(10):779-787
118. Panzram G, Pissarek D, Lundershausen R et al. (1987) Prospektive Verlaufsbeobachtungen beim Langzeitdiabetes. Ergebnisse der Erfurt-Studie. *Dtsch Med Wochenschr* 112(34):1283-1287



## Imprint

### Journal of Health Monitoring

#### Author details

Robert Koch Institute  
Department of Epidemiology and Health Monitoring, Berlin

Corresponding author  
Dr Christin Heidemann  
Robert Koch Institute  
Department of Epidemiology and Health Monitoring  
General-Pape-Str. 62–66  
D-12101 Berlin, Germany  
E-mail: [HeidemannC@rki.de](mailto:HeidemannC@rki.de)

#### Conflicts of interest

The authors declared no conflicts of interest.

#### Note

External contributions do not necessarily reflect the opinions of the Robert Koch Institute.

#### Publisher

Robert Koch Institute  
Nordufer 20  
D-13353 Berlin, Germany

#### Editors

Susanne Bartig, Johanna Gutsche, Dr Franziska Prütz,  
Martina Rabenberg, Alexander Rommel, Dr Anke-Christine Saß,  
Stefanie Seeling, Martin Thißen, Dr Thomas Ziese  
Robert Koch Institute  
Department of Epidemiology and Health Monitoring  
General-Pape-Str. 62–66  
D-12101 Berlin  
Phone: +49 (0)30-18 754-3400  
E-mail: [healthmonitoring@rki.de](mailto:healthmonitoring@rki.de)  
[www.rki.de/journalhealthmonitoring-en](http://www.rki.de/journalhealthmonitoring-en)

#### Typesetting

Gisela Dugnus, Alexander Krönke, Kerstin Möllerke

#### Translation

Simon Phillips/Tim Jack

#### Please cite this publication as

Heidemann C, Scheidt-Nave C (2017) Prevalence, incidence and mortality of diabetes mellitus in adults in Germany – A review in the framework of the Diabetes Surveillance in Germany. *Journal of Health Monitoring* 2(3):98–121  
DOI 10.17886/RKI-GBE-2017-062

ISSN 2511-2708



This work is licensed under a  
Creative Commons Attribution 4.0  
International License.



The Robert Koch Institute is a Federal Institute within  
the portfolio of the German Federal Ministry of Health